During Tuesday’s Current trade, Shares of Precision Drilling Corp (USA) (NYSE:PDS), lost -4.68% to $4.58.
Precision Drilling Corporation ( PDS ) will be attending the 2015 Barclays CEO Energy-Power Conference which is taking place September 8-10, 2015 in New York, New York. Mr. Kevin Neveu, President and Chief Executive Officer, is scheduled to present at 7:45 a.m. Eastern time (5:45 a.m. Mountain time) on Wednesday, September 9, 2015.
Precision Drilling Corporation provides oil and natural gas drilling and related services and products. The company operates through two segments, Contract Drilling Services; and Completion and Production Services. The Contract Drilling Services segment offers onshore well drilling services to exploration and production companies in the oil and natural gas industry. This segment’s services comprise land drilling, directional drilling, and turnkey drilling; and procurement and distribution of oilfield supplies, in addition to manufacture, refurbishment, and sale of drilling and service rig equipment.
Shares of LyondellBasell Industries NV (NYSE:LYB), declined -3.51% to $82.38, during its current trading session.
LyondellBasell (LYB), one of the world’s largest plastics, chemical and refining companies, declared that YPF S.A. and Grupo Inversor Petroquimica S.L. have accepted an offer to purchase LyondellBasell’s Argentina-based, wholly-owned partner Petroken Petroquimica Ensenada S.A. (Petroken). The sale is predictable to close in late 2015 following Brazilian antitrust authority (CADE) approval. The transaction is valued at $145 million on a debt and cash free basis. Based on working capital estimates as of June 30, 2015, predictable cash proceeds are $162 million. Petroken operates a 180 kiloton polypropylene plant in Ensenada and is a leading polypropylene producer in Argentina.
Until closing, Petroken will continue to provide the same level of support, service and high quality products to its customers.
LyondellBasell Industries N.V. operates as a manufacturer of chemicals and polymers, refiner of crude oil, producer of gasoline blending components, and developer and licensor of technologies for production of polymers. The company operates in five segments: Olefins and PolyolefinsAmericas; Olefins and PolyolefinsEurope, Asia, International; Intermediates and Derivatives; Refining; and Technology.
SanDisk Corporation (NASDAQ:SNDK), during its Tuesday’s current trading session decreased -1.69% to $53.64.
SanDisk Corporation ( SNDK), a global leader in flash storage solutions, recently declared it has reached agreement with SK Hynix, Inc. to modify and extend their intellectual property licensing relationship and enter into a multi-year commercial relationship under which SK Hynix will supply its leading-edge DRAM products to SanDisk. These agreements comprise a settlement of the trade secret misappropriation suit filed by SanDisk in 2014.
Under these agreements, which will expire on March 31, 2023, SanDisk will release SK Hynix of its liability pertaining to the trade secret litigation and license certain intellectual property rights to SK Hynix in exchange for license and royalty payments to be made over the duration of the agreement. In addition, SK Hynix has agreed to supply SanDisk with certain volumes of its DRAM products for MCP and SSD applications. The specific terms and conditions of the agreements, counting with respect to economic consideration, are confidential.
SanDisk Corporation designs, develops, manufactures, and markets data storage solutions in the United States and internationally. The company offers removable cards, which are used in various applications and consumer devices, counting digital cameras, camcorders, smartphones, tablets, and eReaders under the SanDisk Ultra, SanDisk Extreme, and SanDisk Extreme PRO brands; and embedded products that are used in mobile phones, tablets, notebooks, and other portable and wearable devices, in addition to in automotive and connected home applications under the brand name iNAND.
Finally, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), decreased -1.38%, to $2.67.
Arena Pharmaceuticals, Inc. (ARNA) stated financial results for the second quarter ended June 30, 2015, and offered a corporate update.
Second Quarter and Recent Developments
Arena Research & Development
- Declared the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334, an oral Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator for autoimmune diseases, being studied in this trial for the treatment of ulcerative colitis.
- Arena and Roivant Sciences Ltd. reached a Development, Marketing and Supply Agreement for nelotanserin, Arena’s internally discovered inverse agonist of the serotonin 2A receptor.
- Declared results from a Phase 1 single-ascending dose clinical trial of APD371, a highly selective and potent cannabinoid 2 (CB2) receptor agonist in development as a potential treatment for pain.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults. It is also developing a portfolio of programs in various therapeutic areas, counting cardiovascular, central nervous system, and metabolic diseases. Its products under development comprise Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, counting potentially pulmonary arterial hypertension that is in Phase II clinical trials.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
